Rectal squamous cell carcinoma (rSCC) is a rare cancer (0.5% of all rectal cancers). It typically presents at an advanced stage and has a poor prognosis. Recently, chemoradiotherapy with organ preservation has become an option for complete response (CR). Surveillance is essential to prompt recognition of recurrence due to its high risk. We present a case of an elderly woman with rSCC stage cT4N1aM0 who underwent a combination of chemotherapy (mitomycin and fluoropyrimidine) and radiotherapy with CR and organ preservation. The patient has been in follow-up for 2 years with digital rectal examination, tumour markers, pelvic MRI, thoracic and upper abdominal CT, proctoscopy and positron emission tomography, with no disease recurrence. This highlights the success of chemoradiotherapy for rSCC treatment, allowing organ preservation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10826491 | PMC |
| http://dx.doi.org/10.1136/bcr-2023-255284 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety and clinical efficacy of neoadjuvant chemoradiation therapy with immunotherapy for organ preservation in ultra-low rectal cancer: preliminary results of the CHOICE-I trial: a prospective cohort study.
Int J Surg
January 2025
Department of Colorectal Surgery.
Objective: To explore the safety and efficacy of neoadjuvant chemoradiotherapy (nCRT) combined with a PD-1 antibody in improving complete clinical response (cCR) and organ preservation in patients with ultra-low rectal cancer.
Methods: This was a prospective phase II, single-arm, open-label trial. Patients with confirmed pMMR status T1-3aN0-1M0 retcal adenocarcinoma were included.
Xenotransplantation (XTx) is an increasingly realistic solution to the organ shortage. Clinical XTx may require off-site procurement in a designated pathogen free (DPF) facility necessitating a period of cold ischemic time during transportation. This study evaluates the impact of different kidney preservation strategies on early graft function in pig-to-baboon XTx in a series of eight cases of pig-to-baboon xenotransplantation performed after five hours of cold ischemic time and compares these results to six cases of pig-to-baboon xenotransplantation performed with minimal ischemic time.
View Article and Find Full Text PDFThe effectiveness of unimodality organ preservation surgical vs organ preservation radiotherapy for early hypopharyngeal cancer: a systematic review protocol.
JBI Evid Synth
January 2025
JBI, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia.
Objective: Our aim is to determine the comparative effectiveness of unimodality organ preservation surgery versus radiotherapy on oncological and functional outcomes in patients with early hypopharyngeal cancer.
Introduction: Early hypopharyngeal cancer is difficult to detect and therefore rarely diagnosed, as patients are often asymptomatic. Radiotherapy is considered the main treatment, although this modality has been compared to the previously used open surgical approach, which may not reflect current surgical options.
Machine perfusion organ preservation: Highlights from the American transplant congress 2024.
Artif Organs
January 2025
Department of Surgery, Division of Transplantation, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
The American Transplant Congress (ATC) 2024, held in Philadelphia, serves as a vital platform for unveiling new research and clinical experience in organ machine perfusion-a key area in organ transplantation. This year's congress gathered 4652 participants from 49 countries, including top experts, to spotlight innovations in machine perfusion across various organ types, such as the liver, kidney, heart, and lung. A total of 87 abstracts on organ machine perfusion were presented.
View Article and Find Full Text PDFA New Oxygen Carrier for Therapeutic Applications.
Drug Test Anal
January 2025
Hemarina SA, Aeropôle Centre, Morlaix, France.
The natural extracellular hemoglobin of the lugworm Arenicola marina (AmHb) has many interesting characteristics: It carries 40 times more oxygen than human hemoglobin; has anti-inflammatory, antibacterial, and antioxidant properties; and is 250 times smaller than a red blood cell. It is nontoxic and nonimmunogenic. It is thus a very promising hemoglobin-based oxygen carrier.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!